Cleavage of Cartilage Oligomeric Matrix Protein (COMP) by ADAMTS4 generates a neoepitope associated with osteoarthritis and other forms of degenerative joint disease
Osteoarthritis (OA) is a highly prevalent joint disease, affecting millions of people worldwide and characterized by degradation of articular cartilage, subchondral bone remodeling and low-grade inflammation, leading to pain, stiffness and disability. Cartilage Oligomeric Matrix Protein (COMP) is a major structural component of cartilage and its degradation has been proposed as a marker of OA severity/progression. Several proteases cleave COMP in vitro, however, it is unclear which of these COMPase activities is prevalent in an osteoarthritic joint. Here, using purified recombinant proteins, we show that A Disintegrin And Metalloproteinase with Thrombospondin motifs 4 (ADAMTS4) is the most potent COMPase, followed by ADAMTS1. Using liquid chromatography-tandem mass spectrometry, we identified several novel cleavage sites in COMP resulting from ADAMTS4 and ADAMTS1 activity. Cleavage at S<sup>77</sup>-V<sup>78</sup> disrupted the pentameric organization of COMP and generated a neopeptide previously identified in the synovial fluid of OA patients. Immunoblots with anti-QQS<sup>77</sup> antibodies confirmed that ADAMTS4 efficiently cleaved this peptide bond. By analyzing five ADAMTS4 variants, we found that the C-terminal spacer domain is strictly necessary for COMPase activity and identified the specific residues involved in the interaction with COMP. An inhibitory anti-ADAMTS4 antibody significantly decreased generation of the COMP QQS<sup>77</sup> neoepitope in human OA cartilage explants, implicating ADAMTS4 as a key protease in generating the QQS<sup>77</sup> neopeptides in OA. Since another major ADAMTS4 substrate is aggrecan, the most abundant proteoglycan in cartilage, these findings highlight that, by cleaving both COMP and aggrecan, ADAMTS4 may play a crucial role in modulating the structural integrity of cartilage.
Authors
- Daniel R. Martin (ORCID: https://orcid.org/0000-0002-3517-3716)
- Alexander F Minns (ORCID: https://orcid.org/0000-0002-5619-4591)
- Rens de Groot (ORCID: https://orcid.org/0000-0002-1044-9499)
- Anders Aspberg (ORCID: https://orcid.org/0000-0002-6588-6944)
- Kazuhiro Yamamoto (ORCID: https://orcid.org/0000-0002-8481-775X)
- Christopher D. Koch (ORCID: https://orcid.org/0000-0001-5220-664X)
- Patricia Badía Folgado
- Danielle A. Debruin (ORCID: https://orcid.org/0000-0003-1851-896X)
- Jonathan Larkin (ORCID: https://orcid.org/0000-0002-1202-9287)
- Salvatore Santamaria (ORCID: https://orcid.org/0000-0001-8670-7776)
- Josefin Ahnström (ORCID: https://orcid.org/0000-0001-5313-6508)
- Suneel Apte (ORCID: https://orcid.org/0000-0001-8441-1226)
- Sumit Bhutada (ORCID: https://orcid.org/0000-0002-5274-5122)
- Patrik Önnerfjord (ORCID: https://orcid.org/0000-0002-2345-2937)
- Sophie Blagg
Institutions
- University of Liverpool (GB)
- Lund University (SE)
- University of Surrey (GB)
- Cleveland Clinic Lerner College of Medicine (US)
- University College London (GB)
- Imperial College London (GB)
- University of Oulu (FI)
Publication Details
- Journal
- Matrix Biology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1016/j.matbio.2024.12.005
- Citations
- 11
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 5.17
Funders
- Arthritis Foundation
- Wellcome Trust
- British Heart Foundation
- Imperial College London
- University of Surrey
- Versus Arthritis
- National Institutes of Health
- Birkbeck, University of London